NCT02073500 Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
| NCT ID | NCT02073500 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Pseudomyxoma Peritonei |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2009-09 |
| Primary Completion | 2022-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2009-09 with a primary completion date of 2022-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to identify biomarkers of disease recurrence and prognosis to optimize patient selection for treatment with cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC), and through animal models to explore different treatment strategies for peritoneal surface malignancies (PSM).
Eligibility Criteria
Inclusion Criteria: * age \> 18 years * confirmed diagnosis of peritoneal surface malignancy * candidate for CRS-HIPEC * written informed consent Exclusion Criteria: * none Approximately 80 patients per year will be eligible for inclusion, as this is the number of patients that annually receive surgical treatment for PSM.
Contact & Investigator
Kjersti Flatmark, MD PhD
PRINCIPAL INVESTIGATOR
Oslo University Hospital
Frequently Asked Questions
Who can join the NCT02073500 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pseudomyxoma Peritonei. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02073500 currently recruiting?
Yes, NCT02073500 is actively recruiting participants. Contact the research team at Kjersti.Flatmark@rr-research.no for enrollment information.
Where is the NCT02073500 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT02073500 clinical trial?
NCT02073500 is sponsored by Oslo University Hospital. The principal investigator is Kjersti Flatmark, MD PhD at Oslo University Hospital. The trial plans to enroll 300 participants.